The latest approval allows Calquence use with bendamustine and rituximab for adults with newly diagnosed mantle cell lymphoma who are not eligible to undergo hematopoietic stem cell ...
AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...
AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...
BeiGene fleshes out global ambition as Brukinsa surpasses AstraZeneca's Calquence in quarterly sales
In a heated competition among BTK inhibitor treatments for blood cancer, BeiGene’s third-to-market Brukinsa has for the first time surpassed AstraZeneca’s Calquence in quarterly sales.
In particular, the company's launched cancer drugs Tagrisso, Imfinzi, Lynparza, and Calquence are well positioned based on leading efficacy in hard-to-treat cancers. These drugs also carry strong ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback